TRDA

Entrada Therapeutics, Inc. Common Stock

11.86

USD

TRDA Earnings Reports

Positive Surprise Ratio

TRDA beat 8 of 17 last estimates.

47%

Next Report

Date of Next Report

Feb 25, 2026

Estimate for Q4 25 (Revenue/ EPS)

$14.16M

-$0.99

Implied change from Q3 25 (Revenue/ EPS)

+777.55%

-6.60%

Implied change from Q4 24 (Revenue/ EPS)

-62.13%

-3400.00%

Entrada Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 06, 2025, TRDA reported earnings of -1.06 USD per share (EPS) for Q3 25, missing the estimate of -0.95 USD, resulting in a -10.55% surprise. Revenue reached 1.61 million, compared to an expected 13.98 million, with a -88.45% difference. The market reacted with a +0.14% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 7 analysts forecast an EPS of -0.99 USD, with revenue projected to reach 14.16 million USD, implying an decrease of -6.60% EPS, and increase of 777.55% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Nurix Therapeutics, Inc. Common stock

Report Date

Jan 28, 2026 For Q4 25

Estimate

-$0.88

Actual

-$0.82

Surprise

+7.66%

Regeneron Pharmaceuticals Inc

Report Date

Jan 30, 2026 For Q4 25

Estimate

$10.84

Actual

$11.44

Surprise

+5.52%

Twist Bioscience Corporation Common Stock

Report Date

Feb 02, 2026 For Q1 26

Estimate

-$0.43

Actual

-$0.50

Surprise

-14.00%

FAQ

What were Entrada Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Entrada Therapeutics, Inc. Common Stock reported EPS of -$1.06, missing estimates by -10.55%, and revenue of $1.61M, -88.45% below expectations.

How did the market react to Entrada Therapeutics, Inc. Common Stock's Q3 2025 earnings?

The stock price moved up 0.14%, changed from $6.94 before the earnings release to $6.95 the day after.

When is Entrada Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Feb 25, 2026.

What are the forecasts for Entrada Therapeutics, Inc. Common Stock's next earnings report?

Based on 7 analysts, Entrada Therapeutics, Inc. Common Stock is expected to report EPS of -$0.99 and revenue of $14.16M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.